# Open Label Treprostinil Raynaud's Study

> **NCT07112183** · PHASE4 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Raynaud's Disease
- Raynaud Phenomena
- Raynauds

## Interventions

- **DRUG:** Oral treprostinil (UT-15C) sustained release tablets

## Key facts

- **NCT ID:** NCT07112183
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-15
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-03-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07112183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07112183, "Open Label Treprostinil Raynaud's Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07112183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*